Overview

Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Efficacy, Safety, and Pharmacokinetics of MP-435 administered for 12 weeks in subjects with rheumatoid arthritis (RA) on stable doses of Methotrexate.
Phase:
Phase 2
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Methotrexate